SANTA ROSA -- Medtronic's Santa Rosa-based CardioVascular division today reported fiscal 2011 revenue increased 16 percent from the previous year to $879 million.
Growth for the division was 13 percent for the fiscal year on a constant currency basis.
"Revenue growth was driven by solid performances in all three businesses, particularly in emerging markets," according to a company statement.
"Particularly, CardioVascular's growth was driven by our innovative portfolio of products including the Integrity stent platform, the CoreValve transcatheter heart valve and the recent U.S. launch of the Endurant stent graft for the treatment of abdominal aortic aneurysms," according to the company.
The CardioVascular division's Coronary and Peripheral, Structural Heart, and Endovascular businesses grew worldwide revenue 12 percent, 13 percent, and 20 percent, respectively, on a constant currency basis.